Abstract
Bromocriptine Mesylate (BC) is an ergot derivative with potent dopamine receptor agonist activity. It is licensed to reduce plasma levels of prolactin. BC has central nervous effects, and is used in patients with Parkinson's disease. There are few randomized controlled trials with BC conducted in moderate brain injury (BI) with conflicting results (1). We aim to present our single center experience on dopaminergic challenge using off-label BC in patients with severe BI.
Highlights
Bromocriptine Mesylate (BC) is an ergot derivative with potent dopamine receptor agonist activity
Dopaminergic challenge with bromocriptine in patients with severe brain injury
We aim to present our single center experience on dopaminergic challenge using off-label BC in patients with severe brain injury (BI)
Summary
Bromocriptine Mesylate (BC) is an ergot derivative with potent dopamine receptor agonist activity. Dopaminergic challenge with bromocriptine in patients with severe brain injury JB Celik*, A Duman, O Arun, IO Onal, O Ilban, AE Sonmez Introduction Bromocriptine Mesylate (BC) is an ergot derivative with potent dopamine receptor agonist activity.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
